莱茵生物
(002166)
| 流通市值：36.57亿 | | | 总市值：60.59亿 |
| 流通股本：4.48亿 | | | 总股本：7.42亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,771,759,914.59 | 1,169,965,060.76 | 725,488,517.4 | 341,215,308.03 |
| 营业收入 | 1,771,759,914.59 | 1,169,965,060.76 | 725,488,517.4 | 341,215,308.03 |
| 二、营业总成本 | 1,555,734,975.45 | 1,055,454,984.4 | 657,852,247.63 | 297,588,999.84 |
| 营业成本 | 1,252,185,948.37 | 840,516,661.85 | 518,022,016.19 | 252,322,968.66 |
| 税金及附加 | 10,623,186.32 | 3,171,474.18 | 2,562,550.64 | 580,949.35 |
| 销售费用 | 63,518,766.06 | 42,410,232.17 | 28,003,103.24 | 11,815,028.89 |
| 管理费用 | 140,967,380.72 | 97,158,131.75 | 62,780,148.91 | 19,750,550.19 |
| 研发费用 | 57,502,496.09 | 47,363,853.57 | 34,432,098.96 | 9,659,639.15 |
| 财务费用 | 30,937,197.89 | 24,834,630.88 | 12,052,329.69 | 3,459,863.6 |
| 其中:利息费用 | 42,238,324.33 | 30,930,108.73 | 19,362,059 | 7,525,723.28 |
| 其中:利息收入 | 4,228,499.93 | 2,920,421.73 | 1,992,883.07 | 982,276.49 |
| 加:公允价值变动收益 | 2,025,062.21 | -6,609,671.77 | -4,502,537.93 | -14,082,608.55 |
| 加:投资收益 | 7,178,829 | 7,179,333.59 | 7,362,916.12 | - |
| 资产处置收益 | -523,831.47 | 6,660.58 | -8,561 | - |
| 资产减值损失(新) | -21,463,296.06 | 672,135.1 | 223,159.57 | -19,840.06 |
| 信用减值损失(新) | -16,076,345.8 | 2,425,743.85 | 2,386,908.91 | 2,840,103.14 |
| 其他收益 | 26,262,839.44 | 15,938,390.85 | 13,843,320.84 | 6,330,600.6 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 213,428,196.46 | 134,122,668.56 | 86,941,476.28 | 38,694,563.32 |
| 加:营业外收入 | 700,624.86 | -8,195.79 | 811.59 | 810.89 |
| 减:营业外支出 | 6,291,647.27 | 6,371,083.91 | 5,474,267.46 | 1,107,283.01 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 207,837,174.05 | 127,743,388.86 | 81,468,020.41 | 37,588,091.2 |
| 减:所得税费用 | 40,663,181.48 | 21,727,600.37 | 13,472,528.13 | 9,703,544.43 |
| 六、净利润 | 167,173,992.57 | 106,015,788.49 | 67,995,492.28 | 27,884,546.77 |
| 持续经营净利润 | 167,173,992.57 | 106,015,788.49 | 67,995,492.28 | 27,884,546.77 |
| 归属于母公司股东的净利润 | 163,008,773.57 | 101,621,708.59 | 64,893,065.27 | 26,790,064.13 |
| 少数股东损益 | 4,165,219 | 4,394,079.9 | 3,102,427.01 | 1,094,482.64 |
| (一)基本每股收益 | 0.22 | 0.14 | 0.09 | 0.04 |
| (二)稀释每股收益 | 0.22 | 0.14 | 0.09 | 0.04 |
| 八、其他综合收益 | 10,901,157.76 | -2,080,182.64 | 3,673,546.89 | 1,454,414.23 |
| 归属于母公司股东的其他综合收益 | 10,901,157.76 | -2,080,182.64 | 3,673,546.89 | 1,454,414.23 |
| 九、综合收益总额 | 178,075,150.33 | 103,935,605.85 | 71,669,039.17 | 29,338,961 |
| 归属于母公司股东的综合收益总额 | 173,909,931.33 | 99,541,525.95 | 68,566,612.16 | 28,244,478.36 |
| 归属于少数股东的综合收益总额 | 4,165,219 | 4,394,079.9 | 3,102,427.01 | 1,094,482.64 |
| 公告日期 | 2025-03-28 | 2024-10-31 | 2024-08-29 | 2024-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |